Pharmaceutics & Novel Drug Delivery Systems

Dr. Pawan Saharan, with a vision to provide Health for all, Invented World’s 1st Immunity Enhancement Drug to treat HIV and host of other Immunity problems via Broad Spectrum Antiviral and New Generation Immuno-modulator- RECEPTOL®. Prestigious Who’s Who American Historical Society (Boston) nominated Dr. Saharan as a World.Leader in healthcare industry responsible for changing the destiny of nations & human race via the creative contribution in the healthcare sector via Receptol that builds body’s own immune system, providing hope to most disenchanted terminally ill patients globally. He has global experience in running healthcare industry, including the Pharmaceuticals MNCs and hospitals at the top management level in India & USA.He created the first truly Nano-Bio-IT Helix via inventing Radha 108 Nano-Peptides for AIDS therapy : RECEPTOL® along with reusable micro-chip diagnostics for AIDS, Cancer, TB and other infections, costing a fraction of current tests creating a paradigm shift in healthcare & bringing smile on Billion Faces who could not afford modern treatment.Late Dr. Abdul Kalam, former President of India, nominated Dr. Saharan for India’s new drug discovery with a funding of Rs 120MM (US$ 3MM), by Dept of Science & technology, Govt. of India.He has a Ph.D. Major in Medicine West Virginia Medical Center, USA & topped First Rate Jawaharlal Nehru University in New Delhi while pursuing Master in Life Sciences and has several International Publications / Presentations including in Top Scientific Journal_ Nature. He has organized several global conferences and lead the Global Impact of Nanobiotechnology in Healthcare. Canadian and UK Govt. invited Dr. Saharan as the state guest in recognition for his contribution to healthcare and technological alliances between North America and India via Canada India. Business Council. UK Prime Minister invited Dr. Saharan in March, 2011 as a key note speaker at the UK India. Business Council for the key note address on affordable health care. American Association for the Advancement of Science (AAAS), Washington DC nominated him for the best US Graduate Student Scientist Award.

Dr. Saharan created the first truly Nano-Bio-IT Helix via inventing Radha 108 Nano-Peptides for AIDS therapy : RECEPTOL® along with reusable micro-chip diagnostics for AIDS, Cancer, TB and other infections, costing a fraction of current tests creating a paradigm shift in healthcare & bringing smile on Billion Faces who could not afford modern treatment.

Mircea Ciuca, MD is currently Global Head of Medical & Clinical Drug Safety at Vifor Pharma in Switzerland. He is leading a team of scientists and physicians involved in all aspects of pharmacovigilance, in both development and post-marketing settings. Mr. Ciuca has about 13 years of experience in drug safety. Prior to join Vifor Pharma he held various positions (Deputy QPPV, Senior Pharmacovigilance Medical Manager, Drug Safety Advisor) at large pharmaceutical companies in The Netherlands, after successfully establishing and leading the medical- scientific department of a medium-size CRO in Rotterdam.

Clinical Drug Safety, clinical practice,Pharmacovigilance

After graduating from Tongji Medical University in Wuhan in 1983, Dr. Tan became a graduate student and studied liver pathology. Then he went to Essen University in Germany, sponsored by the Volkswagen scholarship, to study mesothelioma (1987-1990). After that, he participated in the Human Genome Project at Columbia University in New York (1990-1994). Subsequently, Dr. Tan was a resident and then a chief resident at Yale University Medical Center (1994-1998). He continued as an oncologic pathology fellow at Memorial Sloan-Kettering Cancer Center in New York (1998-1999). Dr. Tan was certified in AP and CP in 1998. He became an assistant professor at Roswell Park Cancer Center in Buffalo (1999-2004). He then worked as an associate professor at the University of Texas Health Center in Houston for two years before I joined MD Anderson Cancer Center in 2006. Dr. Tan was promoted to professor at MD Anderson in 2010, and became the first physician with Asia-heritage holding joint appointments in two clinical disciplines at MD Anderson . Sixty percent of his time is devoted to clinical services, and the rest is committed to research, education, and extramural activities. Dr. Tan’s research is focused on solid tumors, investigating potential biomarkers to assess survivorship and guide personalized medicine. Two of his \English books, Principles of Molecular Diagnostics and Personalized Cancer Medicine and Advances of Surgical Pathology in Gastric Cancer, have been translated into Chinese. Dr. Tan has published 200 peer-reviewed scientific articles and book chapters. Jointly, Dr. Tan has held three patents. He has frequently been invited to present at national and international conferences and seminars. Additionally, he has been invited to chair and co-chair conferences and sections of congresses. Furthermore, Dr. Tan has mentored numerous residents, fellows, and junior pathologists. As the senior medical consultant of Kingmed Medicine, Dr. Tan introduced ASCP to China in 2014, and he has been the honored director of the ASCP Training Center there. He serves on the CAP Committee of Molecular Marketing Panel. Dr. Tan has also served on the editorial board of eight peer-reviewed journals.

Solid tumors, investigating potential biomarkers to assess survivorship and guide personalized medicine

Dr. Dafny received his M.S. and Ph.D. degrees from Hadassah Medical School in Jerusalem in 1965 and 1969, respectively followed by post-docs at Caltech, UCLA, and Columbia. He is currently a professor of Neurobiology at the University of Texas Medical School at Houston. The main focus of his research is on two topics: pain mechanisms, including pain suppression and electro-acupuncture, and drug abuse mechanisms, involving morphine, cocaine, alcohol, ritalin, ecstasy, and Prozac. Behavioral, neurophysiological, pharmacological, endocrinological, and immunological procedures are used, primarily with the rodent as an animal model. The electrophysiological procedures used include single cell and evoked potential recording, electroencephalography (EEG), and brain stimulation. Computerized techniques are used for monitoring animal behavior. He is also involved with several other studies. These concern connections between the nervous, immune, and endocrine systems; brain regulation of hormonal secretion; mechanisms of obesity and satiety; and the electrophysiology of neurotransmitters such as dopamine, serotonin, and norepinephrine, and of peptides, with clinical application to Parkinsonism, Huntington's chorea, and Tardive dyskinesia. In addition, collaborative immunological and endocrinologic studies are conducted with other groups in the Texas Medical Center. Dr. Dafny is a member of several professional organizations including the Society for Neuroscience, Society for Experimental Biology and Medicine, the New York Academy of Sciences, American Society for Pharmacology and Experimental Therapeutics, and the American Physiological Society, among others.

Pain suppression and electro-acupuncture, and drug abuse mechanisms

Tirasak completed his Ph.D. from Faculty of Microbiology, Mahidol University, Bangkok, Thailand. He has his postdoctoral training at NeuroVirology and Cancer biology Center, Temple University, Philadelphia. At present, he is a full professor in Microbiology and Immunology, Graduate Program of Medical Technology, Rangsit University, Thailand. He is interested in various academic subjects of science and liberal arts, in addition of music and sports. His scientific fields mainly focus in viral and cellular interaction, bacteriophage and viral diseases in invertebrate animals. However, his research’s interests expand to viral vaccines, autoimmune disease and cancer biology including the relationship of MHC molecules to some specific diseases and viral vaccines. He enjoys being a reviewer for several journals and an advisor to develop young medical scientists with the wish that they would co-operate and/or succeed to solve all the problematic diseases, now and then, in a proper way with genuine scientific thinking.

Viral and cellular interaction, bacteriophage, viral diseases, viral vaccines, autoimmune disease and cancer biology including the relationship of MHC molecules to some specific diseases and viral vaccines

Yavuz is the chairman of Istanbul Consulting Group. ICG(Istanbul Consulting Group) was founded in 2013 and provided guidance to the Turkish ministry of health as part of a World Bank project.Yavuz is currently the Co-Founder of BioCube İstanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Sumitomo Group/ Expel İlaç Archem Diagnostices Endmed and Diagen. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and director of Avcılar Hospital R&D Center, Chief Medical Officer of Lifematrix GmbH. Previously he worked as the Market Access & Health Policy Director for AIFD in Turkey. Yavuz previously worked as the Vice President of Ipsen pharmaceutical and Director of Teva pharmaceutical in USA managing large clinical trials as well as Investigator Initiated Trials and developing relationships with Key Opinion Leaders. Previously, Yavuz was the Associate Director at KV Pharmaceuticals and Director in Clinical Development department at Forest Laboratories. Yavuz earned his MD from the Faculty of Medicine, University of Ankara in Ankara, Turkey. He completed a clinical internship at Baylor College of Medicine in Houston, followed by continued research training at The University of Texas MD Anderson Cancer Center in Houston. He recently completed his Executive MBA at the Olin Business School at Washington University in St. Louis. Yavuz currently resides with his wife Dr. Kamile Sılay and their two daughters and one son in Ankara,Turkey.

Clinical Research

Alain L Fymat is a medical-physical scientist and an educator who was educated at the Universities of Bordeaux and Paris-Sorbonne, France, and the University of California at Los Angeles. He is the current President/CEO and Professor at the International Institute of Medicine & Science. He was formerly Professor of Radiology, Radiological Sciences, Radiation Medicine (Oncology), Critical Care Medicine, and Physics at several U.S. and European Universities. He has extensively published (~350 scholarly publications) and lectured in several national and international academic, professional, governmental and industrial venues. He is a a Board member of several institutions, Honorable Editor of International Journals of “Cancer Prevention & Current Research”, “Nanomedicine Research”, “Nanomedicine and Nanotechnology” “Open Access Journal of Surgery' and Editor of International Journals of” Nanomedicine”, “Nanobiotechnology”, “Tumor Medicine & Prevention”, “Nanomedicine & Nanoscience Research”, “Cancer Therapy and Oncology”, “Cancer Research & Clinical Oncology (Scientific Synergy Journals)” and “Biomedical Journal of Scientific and Technical Research”.

His current research interests lie at the interface between science and medicine (precision medicine, nanobiotechnology, nanomedicine, genetics/epigenetics/ecogenetics)., and drug delivery across the blood brain barrier).

Wei-Chiang Shen is currently John A. Biles Professor in Pharmaceutical Sciences at the University of Southern California School of Pharmacy. Dr. Shen's research interests focus on the development of novel systems for improving peptide and protein drug delivery. Current research projects in Dr. Shen's laboratory at USC include (1) recombinant fusion proteins for improving peptide and protein drug delivery, and (2) cell-penetrating peptides for cytosolic or nuclear delivery of macromolecular drugs. Dr. Shen has published 150 papers in different areas of biomedical sciences, including biochemistry, cell biology, pharmaceutics, and immunology. He is an inventor or co-inventor of 16 issued and 2 pending US patents in drug delivery and a co-author of the textbook Immunology for Pharmacy Students and a co-editor of the book Antibody-Drug Conjugates – the 21st Century Magic Bullets for Cancer. Dr. Shen was elected to Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 1992 and Fellow of the American Association for the Advancement of Sciences (AAAS) in 2000, and was the recipient of the Grand Prize of Eurand Award for Outstanding Novel Research in Oral Drug Delivery from Controlled Release Society in 2002.

Pharmaceutics, Drug Deivery, Controlled Release

Shawn (Xiaotian) Yin received his Ph. D. in Solid-State Chemistry from University of Waterloo, Canada. He then completed his Post Doctoral fellowship at Department of Materials Sciences and Engineering, Cornell University. Currently, Dr. Yin is a Senior Principal Scientist at Bristol-Myers Squibb Company. His research interests include amorphous and nanomaterials for drug delivery, pharmaceutical polymorphic form studies, API crystal form in drug product, physical characterizations of pharmaceutical substances and powder X-ray diffraction applications in pharmaceutical sciences.

Formulation, Drug Delivery, Drug Development

Vladimir P. Torchilin is a University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. He graduated from the Moscow University with MS in Chemistry, and obtained there his Ph.D. and D.Sc. in Polymer Chemistry and Chemistry of Physiologically Active Compounds in 1971 and 1980, respectively. In 1991, Dr. Torchilin joined MGH/Harvard Medical School as the Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. He was the Chair of the Department of Pharmaceutical Sciences in 1998-2008. His research interests include liposomes, lipid-core micelles, biomedical polymers, drug delivery and targeting, pharmaceutical nanocarriers, experimental cancer immunology. He has published more than 350 original papers (which received more than 30,000 citations), more than 150 reviews and book chapters, wrote and edited 10 books.

Research Interest including Immobilized Enzymes in Medicine, Targeted Delivery of Imaging Agents, Liposomes, Nanoparticulates as Pharmaceutical Carriers, Biomedical Aspects of Drug Targeting, and holds more than 40 patents. He is Editor-in-Chief of Current Drug Discovery Technologies and of Drug Delivery and on the Editorial Boards of many journals including Journal of Controlled Release (Review Editor), Bioconjugate Chemistry, Advanced Drug Delivery Reviews, Molecular Pharmaceutics.

Volkmar Weissig, Sc.D., Ph.D. is a Tenured Full Professor of Pharmacology and Chair of the Department of Pharmaceutical Sciences. Dr. Weissig received his B.S., M.S. and Ph.D. degrees in Chemistry and his postdoctoral Sc.D. degree in Biochemistry and Pharmaceutical Biotechnology from the Martin-Luther University in Halle (Germany). Combined he completed several years of postdoctoral fellowships at the Cardiology Research Center in Moscow (Russia), at the Academic Department of Medicine at the Royal Free Hospital School of Medicine in London (UK), at the Institute of Organic Chemistry at the Czechoslovakian Academy of Science in Prague (CSFR), at the College of Pharmacy and the College of Medicine at the University of Florida, Gainesville, FL and at Harvard Medical School and Massachusetts General Hospital in Boston, MA. Before joining the faculty at Midwestern University, Dr. Weissig was an Assistant Professor of Pharmaceutical Sciences at Northeastern University in Boston, MA. Dr. Weissig holds 16 patents and he has published 98 research papers, review articles and book chapters, mostly in the area of nano drug delivery systems. He also edited and published 8 books. He serves as the Associate Editor of the Journal of Liposome Research and he is member of several other Editorial Boards. In July 2009 Dr. Weissig was inducted into the World Technology Network as a Fellow. In October 2014 Dr. Weissig was elected President of the World Mitochondria Society.

Dr. Weissig’s major research interests lie in the areas of Mitochondrial Medicine and Pharmaceutical Nanotechnology. In particular, his laboratory has pioneered the design and development of mitochondria-targeted nano drug delivery systems, which have opened new strategies for mitochondrial gene therapy, for apoptosis-based anticancer chemotherapies and for controlling and manipulating the redox status of mammalian mitochondria.

Professor Raid Alany has over 25 years of international experience in pharmacy education, pharmaceutics and drug delivery research. His academic journey spans three continents, namely, Asia, Oceania and Europe. He received his PhD in drug delivery from the University of Otago, Dunedin New Zealand in 2001; was appointed as a Lecturer at the School of Pharmacy, The University of Auckland, Auckland, New Zealand. He joined Kingston University London as Professor (Chair) of Pharmaceutics in January 2011 and was appointed as Research Director for the School of Pharmacy and Chemistry in December 2013. Raid is an author on over 200 scientific research publications (papers and abstracts), a book and seven book chapters. Professor Alany acts as Editor-in-Chief for Pharmaceutical Development and Technology, Section Editor for Clinical and Experimental Ophthalmology the official journal of the Royal Australian and New Zealand College of Ophthalmologists; Chief Patron, Drug Development and Therapeutics, a publication of Organization of Pharmaceutical Unity with BioAllied Sciences (OPUBS). He serves on the Editorial Board of the following journals: Current Medical Research and Opinion, BioMed Research International, Journal of Drug Delivery Science and Technology, Current Drug Delivery, Pharmaceutics MDPI, and Drug Delivery Letters. He is the Immediate Past President of the New Zealand Chapter of the Controlled Release Society (NZCRS), Young Scientist Committee of the Controlled Release Society. Raid won several awards such as Microscopy New Zealand Young Scientists Award in 1999 The University of Auckland's Vice Chancellor's Early Career Research Excellence Award in 2003, the Controlled Release Society Veterinary Programme co-chair/ chair Distinguished Service Awards in 2008/2009 and the Spark Ideas Challenge, Uniservices Prize and Chiasma Prize in 2011. He consults for human and veterinary pharmaceutical companies in New Zealand and Singapore and is an inventor on several international patents.

Ophthalmic Drug Delivery; Lipid and Surfactant Based Drug Delivery Systems; Delivery of Antisense Oligonucleotides and siRNA; In Situ Gelling Systems; Veterinary Pharmaceuticals

Arwyn gained his PhD in protein biochemistry and crystallography at Birkbeck College, University of London. Then he undertook postdoctoral positions investigating endocytosis at the University of Liverpool and Harvard University, Boston USA. In 2000 he was awarded a European Molecular Biology Organization fellowship to work at the European Molecular Biology Laboratory (EMBL), Heidelberg Germany, and continued at the EMBL when he was awarded an Alexander von Humboldt Foundation Scholarship. He was appointed as Lecturer at the Cardiff School of Pharmacy and Pharmaceutical Sciences at Cardiff University in 2002 where he is now a Professor in Membrane Traffic and Drug Delivery. In addition to scientific research, Arwyn also has a very wide interest in public engagement with science and has organised a number of large exhibitions focusing on e.g. stem cell biology, tissue engineering, pollination and neuroscience. Through a BBC scholarship, he gained a Diploma in Journalism qualification from Bangor University in 2001 and for a number of years he has been a regular face and voice in the Welsh media discussing scientific issues.

Projects in his lab fall under cancer cell biology, endocytosis and drug delivery, concentrating on linking endocytosis research to enhance our capacity to deliver therapeutics to defined regions of cells. He actively collaborates with a number of national and international groups including his recent strong involvement with COMPACT (http://www.compact-research.org/) - an academic/industrial consortium collaborating on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets. Arwyn has published widely within the fields of endocytosis and drug delivery especially within the remit of early endosomal traffic and the utilization of Cell Penetrating Peptides as drug delivery vectors. He currently sits on the Editorial Board of the Journal of Controlled Release and Membranes.

Amiram Goldblum is the Head of the Molecular Modeling and Drug Design and Discovery Unit at the Institute for Drug Research of the Hebrew University. Following a BSc in Chemistry and Physics and a MSc in QM studies of molecular spectra, his PhD is in Organic Reaction Mechanisms (Mechoulam, Hebrew U). He completed his Post-doctoral studies of Quantum Biochemistry (Paris), QSAR and QM reaction mechanisms (California). He receieved his first award at the American Chemical Society National Meeting in Washington DC 2000 for his algorithm called "Iterative Stochastic Elimination" (ISE) used to solve extremely complex combinatorial problems and focuses in recent years on Molecular Discovery by Chemoinformatics.

Computational methods for Drug Delivery Systems

Gabriele Sadowski is full Professor for Thermodynamics. Her main fields of research are thermodynamics of biological and pharmaceutical systems. She has published about 150 papers, is Chair of the German Working Party of Thermodynamics and member of the German Academy of Technical Sciences. 2011, she received the prestigious Leibniz award.

Thermodynamics of Biological and Pharmaceutical systems.

Costas Kiparissides is a full time Professor of Chemical Engineering Department (AUTH) since 1981. He was Director of CPERI (2001-2006) and CERTH (2005-2010). He received his diploma in Chemical Engineering from NTUA (1971) and his Ph.D. from McMaster University (1978). He has supervised more than fifty Ph.D. students, 160 diploma theses and has presented more than 300 invited seminars and lectures. He has published 210 papers in refereed journals, 430 conference papers and 24 books and reports. His research interests include advanced multi-scale modeling of chemical and biological systems, functional materials, drug delivery systems, and microbial production of functional biopolymers.

Pharmaceutics and Novel Drug Delivery Systems

Mino Caira has directed the Centre for Supramolecular Chemistry Research at the University of Cape Town (UCT) since 2005. He retired as Professor of Physical Chemistry in 2014 and was subsequently appointed as a Senior Scholar in the Department of Chemistry at UCT. His expertise is in the area of solid-state chemistry of drug polymorphs and novel multi-component systems containing active pharmaceutical ingredients. He has published over 300 papers in international journals and since 2009 has served on the Editorial Advisory Board of the Journal of Pharmaceutical Sciences.

Crystalline supramolecular systems containing drug molecules and Drug Delivery Systems

B. B. Barik has completed his Ph.D. in 1993 from Jadavpur University, Kolkata, India. He is the Professor in the department of Pharmaceutics, College of Pharmacy, Jazan University, KSA. Earlier he worked as professor and head in the Univ Dept of Pharm Sci, Utkal University, Bhubaneswar, India and College of Pharmaceutical Sci, Berhampur, Odisha. He has published more than 50 papers in reputed journals and presented more than 100 papers in national and international conferences. He is serving as reviewer and editorial board member of reputed journals.

Novel Drug Delivery and Pharmaceutics

Şennur Görgülü Kahyaoğlu has completed her MSc degree from Anadolu University Department of Advanced Technologies-Biotechnology and continued Doctoral studies at the same University Graduate School of Health Sciences, Department of Pharmacology. She is responsible for xCELLigence RTCA MP System, flow cytometer, confocal microscope and cell culture laboratory. She is pursuing her studies on nano-biotechnology for novel drug research and development. She has 3 papers in refereed journals and has attended more than 15 conferences.

Pharmaceutics and Novel Drug Delivery Systems

Bahar Demir has graduated from EskiÅŸehir Osmangazi University Department of Biology. She is doing her Post-graduation at Anadolu University Department of Biochemistry. She is studying on anti-cancer agents for novel drug research and development. She has taken part in 2 projects and has attended more than 5 conferences.

Pharmaceutics and Novel Drug Delivery Systems

Meliha Ekinci received her Master’s degree in Radiopharmacy from Ege University (Turkey) in 2015. She is currently a Research Assistant at Radiopharmacy Department and also a Doctoral student at Biopharmaceutics and Pharmacokinetics Department, Ege University. She has already published 4 papers in reputed journals. Her research interest is in radiolabeled and evaluated newly developed radiopharmaceuticals for diagnosis of different cancer types.

Pharmaceutics and Novel Drug Delivery Systems

Nehal has got her Master’s degree in Pharmaceutical Chemistry from the German University in Cairo in 2015. She is currently working as a Research Assistant in Zewail City of Science and Technology. Moreover, Nehal is a Drug Design Ph.D. student in Zewail City. She has 2 publications in reputable international journals as well as an accepted Poster in another international conference.

Pharmaceutics and Novel Drug Delivery Systems

Sahar Awwad completed both her Bachelor’s in Pharmacy and MSc in Drug Delivery. She is in the final year of her PhD at UCL School of Pharmacy and UCL Institute of Ophthalmology, under the supervision of Professor Steve Brocchini and Professor Sir Peng Tee Khaw.

Pharmaceutics and Novel Drug Delivery Systems

Merari Tumin Chevalier has completed a 5 years degree in Chemistry from National University of Mar del Plata. Currently, she is working on her PhD thesis at the Research Institute in Materials Science and Technology (INTEMA)- CONICET (Argentina), particularly in the Group of Polymer Matrix Composite Materials led by Dra. Vera Alvarez. The goal of her work is to develop and study effective biopolymeric drug carriers. At the present time, she is doing a six month residence in the Polymer Science and Technology Institute (ICTP)-CSIC (Madrid) in order to acquire new knowledge regarding the preparation and characterization of polymeric nanoparticles.

Pharmaceutics and Novel Drug Delivery Systems

Shayan F Lahiji has completed his BS and MS from Yonsei University (South Korea) and is currently doing his PhD at the same university. Because of his outstanding contribution to science and new novel delivery systems, he has been awarded in different fields of science for “The best poster presenter” from 3rd world biotechnology conference, “The best research award” from Yonsei University and “The best academic poster” from BK21 PLUS Research Symposium and more. He has published papers in reputed journals such as “Scientific Reports” from Nature Publishing Group and “Biomaterials” from Elsevier.

Pharmaceutics and Novel Drug Delivery Systems

Jesus Izaguirre Carbonell obtained his degree in pharmacy at Universidad Miguel Hernandez in Spain. Thereafter, he moved to Japan where he is currently completing his PhD at Tokyo University of Science under Prof. Sugawara supervision and where he also obtained his master degree. He has published 4 papers for obtaining his PhD degree including renowed journals.

Pharmaceutics and Novel Drug Delivery Systems

N Storozhylova is a Erasmus Mundus NanoFar PhD student at University of Nantes and University of Santiago de Compostela, 2013-2016.

Pharmaceutics and Novel Drug Delivery Systems